TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Systemic lidocaine infusion may improve the patients' recovery quality and chronic post surgical pain after robot-assisted thyroidectomy


Options:
A: Arm Label: Lidocaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
B: Arm Label: Group L; Type: EXPERIMENTAL; Interventions: Drug: Systemic intravenous lidocaine infusion | Arm Label: Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline infusion | Intervention Type: DRUG; Name: Systemic intravenous lidocaine infusion; Assigned to Arm(s): Group L | Intervention Type: DRUG; Name: normal saline infusion; Assigned to Arm(s): Group C
C: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Intraperitoneal lidocaine irrigation group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraperitoneal lidocaine irrigation group | Arm Label: Intravenous normal saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intraperitoneal lidocaine irrigation group; Assigned to Arm(s): Intraperitoneal lidocaine irrigation group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Intravenous normal saline group
D: Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine Intravenous Infusion | Intervention Type: DRUG; Name: Lidocaine Intravenous Infusion; Assigned to Arm(s): Lidocaine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan
Brief Summary: The objective of the projects is to Develop and implement a Package of interventions that will comprise of an augmented communication and counseling strategy coupled with private sector involvement and a combined Oral Polio Vaccine and Inject able Polio Vaccine approach during the Polio campaigns followed by the evaluation of this project for acceptability, feasibility and effectiveness of the intervention Package.


Options:
A: Arm Label: Dulce family partner intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Project dulce | Arm Label: Safety intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Safety intervention | Intervention Type: BEHAVIORAL; Name: Project dulce; Assigned to Arm(s): Dulce family partner intervention | Intervention Type: BEHAVIORAL; Name: Safety intervention; Assigned to Arm(s): Safety intervention
B: Arm Label: P3 Vaccine Promotion Package; Type: EXPERIMENTAL; Interventions: Behavioral: P3 Vaccine Promotion Package. | Arm Label: No P3 vaccine promotion package intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: P3 Vaccine Promotion Package.; Assigned to Arm(s): P3 Vaccine Promotion Package
C: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization, Biological: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA | Intervention Type: BEHAVIORAL; Name: Enhanced Community mobilization; Assigned to Arm(s): Group B, Group C | Intervention Type: BIOLOGICAL; Name: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA; Assigned to Arm(s): Group C
D: Arm Label: Participatory; Type: EXPERIMENTAL; Interventions: Behavioral: Participatory | Arm Label: Efficient; Type: EXPERIMENTAL; Interventions: Behavioral: Efficient | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Participatory; Assigned to Arm(s): Participatory | Intervention Type: BEHAVIORAL; Name: Efficient; Assigned to Arm(s): Efficient

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan
Brief Summary: The objective of the projects is to Develop and implement a Package of interventions that will comprise of an augmented communication and counseling strategy coupled with private sector involvement and a combined Oral Polio Vaccine and Inject able Polio Vaccine approach during the Polio campaigns followed by the evaluation of this project for acceptability, feasibility and effectiveness of the intervention Package.


Options:
A: Arm Label: Cell-phone assisted; Type: EXPERIMENTAL; Interventions: Device: Cell-phone | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cell-phone; Assigned to Arm(s): Cell-phone assisted
B: Arm Label: Conditional Cash Transfer; Type: EXPERIMENTAL; Interventions: Other: Conditional Cash Transfer, Other: Standard Agricultural Package, Other: Parenting Skills Classes | Arm Label: Unconditional Cash Transfer; Type: EXPERIMENTAL; Interventions: Other: Unconditional Cash Transfers, Other: Standard Agricultural Package, Other: Parenting Skills Classes | Arm Label: Control; Type: OTHER; Interventions: Other: Standard Agricultural Package, Other: Parenting Skills Classes | Intervention Type: OTHER; Name: Conditional Cash Transfer; Assigned to Arm(s): Conditional Cash Transfer | Intervention Type: OTHER; Name: Unconditional Cash Transfers; Assigned to Arm(s): Unconditional Cash Transfer | Intervention Type: OTHER; Name: Standard Agricultural Package; Assigned to Arm(s): Conditional Cash Transfer, Control, Unconditional Cash Transfer | Intervention Type: OTHER; Name: Parenting Skills Classes; Assigned to Arm(s): Conditional Cash Transfer, Control, Unconditional Cash Transfer
C: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization, Biological: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA | Intervention Type: BEHAVIORAL; Name: Enhanced Community mobilization; Assigned to Arm(s): Group B, Group C | Intervention Type: BIOLOGICAL; Name: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA; Assigned to Arm(s): Group C
D: Arm Label: One time standard verbal counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Short message service | Intervention Type: BEHAVIORAL; Name: Short message service; Assigned to Arm(s): SMS Reminders

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)


Options:
A: Arm Label: Aclidinium Bromide / Formoterol Fumarate; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate | Arm Label: Salmeterol / Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone | Intervention Type: DRUG; Name: Aclidinium Bromide / Formoterol Fumarate; Assigned to Arm(s): Aclidinium Bromide / Formoterol Fumarate | Intervention Type: DRUG; Name: Salmeterol / Fluticasone; Assigned to Arm(s): Salmeterol / Fluticasone propionate
B: Arm Label: Aclidinium/Formoterol 400/6 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium/Formoterol 400/12 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium monotherapy 400 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Formoterol monotherapy 12 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/6 μg | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/12 μg | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium monotherapy 400 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): Formoterol monotherapy 12 μg
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)


Options:
A: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
B: Arm Label: Umeclidinium 62.5 mcg + placebo; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium, Drug: Umeclidinium matching placebo | Arm Label: Tiotropium 18mcg + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Tiotropium matching placebo | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Umeclidinium matching placebo; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18mcg + placebo | Intervention Type: DRUG; Name: Tiotropium matching placebo; Assigned to Arm(s): Tiotropium 18mcg + placebo
C: Arm Label: Aclidinium Bromide / Formoterol Fumarate; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate | Arm Label: Salmeterol / Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone | Intervention Type: DRUG; Name: Aclidinium Bromide / Formoterol Fumarate; Assigned to Arm(s): Aclidinium Bromide / Formoterol Fumarate | Intervention Type: DRUG; Name: Salmeterol / Fluticasone; Assigned to Arm(s): Salmeterol / Fluticasone propionate
D: Arm Label: Fluticasone Furoate / GW642444 (vilanterol); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg | Arm Label: Fluticasone Propionate / salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg; Assigned to Arm(s): Fluticasone Furoate / GW642444 (vilanterol) | Intervention Type: DRUG; Name: Fluticasone Propionate 250mcg/ salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate / salmeterol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism
Brief Summary: We are studying an investigational drug called intranasal oxytocin (Syntocinon®). Syntocinon® has been approved by the U.S. Food and Drug Administration for use in helping women breastfeed, but it has not been approved for use in children with ASD. However, there is previous research conducted that has indicated that after administration of oxytocin, adults with ASD demonstrated improvements in social cognition, and reduced repetitive behaviours and anxiety. There is also early research to suggest that children may also benefit in these areas. The purpose of this study is to test if oxytocin works to help children and adolescents with ASD.


Options:
A: Arm Label: Bumetanide; Type: EXPERIMENTAL; Interventions: Drug: bumetanide | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: bumetanide | Intervention Type: DRUG; Name: bumetanide; Assigned to Arm(s): Bumetanide, Control
B: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism
Brief Summary: We are studying an investigational drug called intranasal oxytocin (Syntocinon®). Syntocinon® has been approved by the U.S. Food and Drug Administration for use in helping women breastfeed, but it has not been approved for use in children with ASD. However, there is previous research conducted that has indicated that after administration of oxytocin, adults with ASD demonstrated improvements in social cognition, and reduced repetitive behaviours and anxiety. There is also early research to suggest that children may also benefit in these areas. The purpose of this study is to test if oxytocin works to help children and adolescents with ASD.


Options:
A: Intervention Type: DRUG; Name: Risperidone, divalproex; Assigned to Arm(s): N/A
B: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine (Zyprexa) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: olanzapine (Zyprexa); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism
Brief Summary: We are studying an investigational drug called intranasal oxytocin (Syntocinon®). Syntocinon® has been approved by the U.S. Food and Drug Administration for use in helping women breastfeed, but it has not been approved for use in children with ASD. However, there is previous research conducted that has indicated that after administration of oxytocin, adults with ASD demonstrated improvements in social cognition, and reduced repetitive behaviours and anxiety. There is also early research to suggest that children may also benefit in these areas. The purpose of this study is to test if oxytocin works to help children and adolescents with ASD.


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Open-Label Donepezil; Type: EXPERIMENTAL; Interventions: Drug: Donepezil | Arm Label: Donepezil - Blinded; Type: EXPERIMENTAL; Interventions: Drug: Donepezil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): Donepezil - Blinded, Open-Label Donepezil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine, Behavioral: Parent Management Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Parent Management Training | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: BEHAVIORAL; Name: Parent Management Training; Assigned to Arm(s): 1, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ACTonHEART Study: a Randomized Controlled Clinical Trial of Acceptance and Commitment Therapy in Cardiac Patients
Brief Summary: The study will determine whether a brief intervention program based on Acceptance and Commitment Therapy can be effective for the reduction of modifiable risk factors and improvement of psychological well-being in patients referred to cardiac rehabilitation


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2
B: Arm Label: Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical therapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Psychotherapy | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Control
C: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ACTonHEART Study: a Randomized Controlled Clinical Trial of Acceptance and Commitment Therapy in Cardiac Patients
Brief Summary: The study will determine whether a brief intervention program based on Acceptance and Commitment Therapy can be effective for the reduction of modifiable risk factors and improvement of psychological well-being in patients referred to cardiac rehabilitation


Options:
A: Arm Label: Standard group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard | Arm Label: Mind&Life (standard + intervention) group; Type: EXPERIMENTAL; Interventions: Behavioral: Mind&Life, Behavioral: Standard | Intervention Type: BEHAVIORAL; Name: Mind&Life; Assigned to Arm(s): Mind&Life (standard + intervention) group | Intervention Type: BEHAVIORAL; Name: Standard; Assigned to Arm(s): Mind&Life (standard + intervention) group, Standard group
B: Arm Label: Diabetes Self Management Education (DSME) + Mind-STRIDE; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-STRIDE | Arm Label: DSME alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mind-STRIDE; Assigned to Arm(s): Diabetes Self Management Education (DSME) + Mind-STRIDE
C: Arm Label: Standard lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard lifestyle intervention | Arm Label: Mind-body lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-body lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Mind-body lifestyle intervention; Assigned to Arm(s): Mind-body lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Standard lifestyle intervention; Assigned to Arm(s): Standard lifestyle intervention
D: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care

Answer: D